Article Per Year (5 Year)
p-Index From 2021 - 2026
0
P-Index
This Author published in this journals
All Journal MEDICINUS
Dewi, Juliani
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Perkembangan Pemeriksaan Interferon-Gamma Release Assay (IGRA) dengan Metode T-SPOT.TB serta Aspek Klinis Pelaporan Hasil Dewi, Juliani
MEDICINUS Vol. 33 No. 1 (2020): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (440.107 KB) | DOI: 10.56951/medicinus.v33i1.5

Abstract

Latent tuberculosis infection (LTBI) screening and its treatment play important role in controlling tuberculosis (TB). Healthcare workers are known to be at high risk of latent TB infection. CDC suggests that every healthcare service should have TB controlling program. CDC recommends IGRA test for people who have history of contact with atypical mycobacteria patiens, screening in pregnancy, healthcare worker screening, and serial evaluation for Mycobacterium tuberculosis (MTB) infection. IGRA test kits that are commercially available are QFT and T-SPOT.TB. Term “indeterminate” is used as a borderline value in QFT, but in T-SPOT.TB, it means the result is invalid. Term "borderline zone" is used in T-SPOT.TB, but not in QFT. T-SPOT.TB uses borderline zone which is designed to reduce uncertainty result in narrow range around single cut-off point. There are still no recommendations to use IGRA test for therapeutic monitoring.
Co-Authors